Clearmind Medicine Inc. (NASDAQ: CMND | CSE: CMND | FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced it will present at the 2023 OurCrowd Global Investor Summit, that will take place on the 15th of February 2023, in Jerusalem, Israel.
Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer, to present the company and share it experience from recent Nasdaq IPO. The presentation will be part of special session sponsored by leading international law firm, Greenberg Traurig, hosted by shareholder at the firm, Mr. David Huberman. The session will focus on “IPOs in a Down Market” and will take place at 12:00 PM at the GT Lounge, Room 314.
About Greenberg Traurig’s Tel Aviv Office and Israel Practice:
Greenberg Traurig’s Tel Aviv office is the only major international law firm with a multidisciplinary, registered office in Tel Aviv and serves as a gateway for Israeli businesses and entrepreneurs seeking opportunities around the world, as well as for clients exploring opportunities within Israel. The office provides Israeli and foreign clients access to legal services in the U.S., London, Amsterdam, Germany, Poland, China, Japan, Latin America, MENA region and other international jurisdictions and also represents non-Israeli companies seeking opportunities within Israel. The firm’s Israel Practice continuously provides clients a global network of professionals with the legal experience, business alliances, technical knowledge, political experience, language capabilities, and cultural understanding needed in Israel, to deliver strategic advice to our clients. The Greenberg Traurig Tel Aviv office and Israel Practice attorneys offer a unique multi-disciplinary, integrated team of professionals to assist clients with a range of corporate and commercial law issues in numerous industries.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.